Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune”